Trifluridine/tipiracil plus ramucirumab in gastric cancer
Mené au Japon sur 64 patients atteints d'un cancer de l'estomac de stade avancé, cet essai de phase II évalue l'efficacité, du point de vue du taux de contrôle de la maladie, et la toxicité d'un traitement à base de trifluridine/tipiracil en combinaison avec le ramucirumab après l'échec d'une ou plusieurs lignes thérapeutiques
As treatment options expand, patients with advanced gastric or gastro-oesophagealjunction cancer are living longer and are more likely to receive multiple lines oftherapy. The armamentarium now contains combinations of fluoropyrimidines (includingtrifluridine/tipiracil), platinum agents, taxanes, and camptothecins, as well as theantiangiogenesis agent ramucirumab, trastuzumab, and anti-PD-1 immunotherapy. Thiswelcome development leads us to ask, is there an optimal sequence of therapies? Identifyingthis sequence is ideally guided by understanding the effect of each individual treatment—adverseand favourable—on the host, tumour, and microenvironment, and the ability of subsequenttreatment to exploit any therapy-induced modulations.
The Lancet Gastroenterology & Hepatology , commentaire, 2020